Dysregulation of the complement cascade is increasingly being recognised as a key drive of pathology in a broad range of conditions such as chronic renal disease (eg. IgA nephropathy, C3 glomerulopathy amongst others) as well as diseases of the neurological system such as multiple sclerosis and Alzheimer’s disease. The role of FHR proteins is also emerging and thereby creating an opportunity for CTx to deploy its novel assets to treat such conditions.